Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia
Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an i...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2017-05, Vol.119 (9), p.1401-1406 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1406 |
|---|---|
| container_issue | 9 |
| container_start_page | 1401 |
| container_title | The American journal of cardiology |
| container_volume | 119 |
| creator | Pokorney, Sean D., MD, MBA Mi, Xiaojuan, PhD Hammill, Bradley G., DrPH Allen LaPointe, Nancy M., PharmD, MHS Curtis, Lesley H., PhD Al-Khatib, Sana M., MD, MHS |
| description | Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012. Patients were identified through a search for antiarrhythmic medication fills with a supply covering January 1 of the cohort year. Adjusted logistic regression modeling evaluated the association between patient characteristics and antiarrhythmic medication use. The 2007 (n = 2,334) and 2012 (n = 3,892) Medicare Part D cohorts had similar demographics: median age 76 years, 64%-67% male, and 87%-89% white. Of the 2007 cohort, 1,380 (59%) patients were on a beta blocker, and 484 (20.7%) were on an antiarrhythmic medication (70% amiodarone and 20% sotalol). Between 2007 and 2012, there was a statistically significant higher use of any antiarrhythmic medication (p = 0.014), beta blockers (p |
| doi_str_mv | 10.1016/j.amjcard.2017.01.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1881269004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914917301297</els_id><sourcerecordid>1888122569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-d2712024bb854ddd8f165ba1eb3ae703f590a8274d55ef13d0f63e778313e1f53</originalsourceid><addsrcrecordid>eNqFkkuLFDEQgBtR3HH1JygBL166rUr6eVGWWR8LKwru6jGkk2ombT_GJL0w_8CfbZoZFfbiKRR8Vamqr5LkOUKGgOXrPlNjr5UzGQesMsAMBDxINlhXTYoNiofJBgB42mDenCVPvO9jiFiUj5MzXoscRQmb5NetJzZ37GIKVjm3O4TdaDX7RMZqFew8eWanU-iIfVEusMv4BEtT8Oy7DTumJnY17gc1BdUOxLaxKTvfkQvk0kvqbOvsMKgwu0ga9i0mOquXQTl2o_TusA5h1dPkUacGT89O73ly-_7dzfZjev35w9X24jrVeV6H1PAKOfC8besiN8bUHZZFq5BaoagC0RUNqJpXuSkK6lAY6EpBVVULFIRdIc6TV8e6ezf_XMgHOVqvKTY40bx4iXWNvGwA8oi-vIf28-Km2N1KRYwXZROp4khpN3vvqJN7Z0flDhJBrqpkL0-q5KpKAsqoKua9OFVf2pHM36w_biLw9ghQXMedJSe9jlvX0YUjHaSZ7X-_eHOvgh7sFE0OP-hA_t800nMJ8ut6L-u5YCUAeVOJ38QyvO8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1888122569</pqid></control><display><type>article</type><title>Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pokorney, Sean D., MD, MBA ; Mi, Xiaojuan, PhD ; Hammill, Bradley G., DrPH ; Allen LaPointe, Nancy M., PharmD, MHS ; Curtis, Lesley H., PhD ; Al-Khatib, Sana M., MD, MHS</creator><creatorcontrib>Pokorney, Sean D., MD, MBA ; Mi, Xiaojuan, PhD ; Hammill, Bradley G., DrPH ; Allen LaPointe, Nancy M., PharmD, MHS ; Curtis, Lesley H., PhD ; Al-Khatib, Sana M., MD, MHS</creatorcontrib><description>Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012. Patients were identified through a search for antiarrhythmic medication fills with a supply covering January 1 of the cohort year. Adjusted logistic regression modeling evaluated the association between patient characteristics and antiarrhythmic medication use. The 2007 (n = 2,334) and 2012 (n = 3,892) Medicare Part D cohorts had similar demographics: median age 76 years, 64%-67% male, and 87%-89% white. Of the 2007 cohort, 1,380 (59%) patients were on a beta blocker, and 484 (20.7%) were on an antiarrhythmic medication (70% amiodarone and 20% sotalol). Between 2007 and 2012, there was a statistically significant higher use of any antiarrhythmic medication (p = 0.014), beta blockers (p <0.0001), mexiletine (p = 0.005), and ranolazine (p <0.0001), while amiodarone use remained unchanged (p = 0.53). After multivariable adjustment, male gender and renal disease were associated with higher antiarrhythmic medication use. In conclusion, although antiarrhythmic medication and beta blocker use in patients with VT increased over time, <1 in 4 patients were on an antiarrhythmic medication and only 65% of the patients were on a beta blocker.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2017.01.030</identifier><identifier>PMID: 28341360</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Ablation ; Acute coronary syndromes ; Adrenergic beta-Antagonists - therapeutic use ; Aged ; Aged, 80 and over ; Amiodarone ; Amiodarone - therapeutic use ; Anemia ; Anomalies ; Anti-Arrhythmia Agents - therapeutic use ; Antiarrhythmics ; Arrhythmia ; Atenolol ; Cancer ; Cardiac arrhythmia ; Cardiomyopathy ; Cardiovascular ; Cardiovascular disease ; Cardiovascular diseases ; Cerebral infarction ; Chronic obstructive pulmonary disease ; Circulation ; Classification ; Clinical trials ; Codes ; Complications ; Congenital defects ; Congestive heart failure ; Coronary artery ; Coronary artery disease ; Coronary vessels ; Damage ; Databases, Factual ; Death, Sudden, Cardiac - prevention & control ; Defibrillators, Implantable ; Diabetes mellitus ; Diagnosis ; Drugs ; Electric Countershock ; Electrocardiography ; Enrollments ; Female ; Generic drugs ; Government programs ; Guidelines ; Health care ; Health risks ; Heart ; Heart attacks ; Heart failure ; Hospitals ; Humans ; Hypertension ; Incidence ; Intervention ; Ischemia ; Kidney transplantation ; Logistic Models ; Lung diseases ; Male ; Mathematical models ; Medical instruments ; Medicare ; Medicare Part D ; Mexiletine - therapeutic use ; Mortality ; Myocardial infarction ; Patients ; Population studies ; Populations ; Prescription drugs ; Prevention ; Quality of life ; Ranolazine - therapeutic use ; Regression analysis ; Renal failure ; Risk ; Skin ; Sodium Channel Blockers - therapeutic use ; Sotalol - therapeutic use ; Statistical tests ; Stroke ; Survival ; Tachycardia, Ventricular - therapy ; Terminology ; Transplants & implants ; United States ; Ventricle</subject><ispartof>The American journal of cardiology, 2017-05, Vol.119 (9), p.1401-1406</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited May 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-d2712024bb854ddd8f165ba1eb3ae703f590a8274d55ef13d0f63e778313e1f53</citedby><cites>FETCH-LOGICAL-c448t-d2712024bb854ddd8f165ba1eb3ae703f590a8274d55ef13d0f63e778313e1f53</cites><orcidid>0000-0002-4345-0816</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914917301297$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28341360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pokorney, Sean D., MD, MBA</creatorcontrib><creatorcontrib>Mi, Xiaojuan, PhD</creatorcontrib><creatorcontrib>Hammill, Bradley G., DrPH</creatorcontrib><creatorcontrib>Allen LaPointe, Nancy M., PharmD, MHS</creatorcontrib><creatorcontrib>Curtis, Lesley H., PhD</creatorcontrib><creatorcontrib>Al-Khatib, Sana M., MD, MHS</creatorcontrib><title>Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012. Patients were identified through a search for antiarrhythmic medication fills with a supply covering January 1 of the cohort year. Adjusted logistic regression modeling evaluated the association between patient characteristics and antiarrhythmic medication use. The 2007 (n = 2,334) and 2012 (n = 3,892) Medicare Part D cohorts had similar demographics: median age 76 years, 64%-67% male, and 87%-89% white. Of the 2007 cohort, 1,380 (59%) patients were on a beta blocker, and 484 (20.7%) were on an antiarrhythmic medication (70% amiodarone and 20% sotalol). Between 2007 and 2012, there was a statistically significant higher use of any antiarrhythmic medication (p = 0.014), beta blockers (p <0.0001), mexiletine (p = 0.005), and ranolazine (p <0.0001), while amiodarone use remained unchanged (p = 0.53). After multivariable adjustment, male gender and renal disease were associated with higher antiarrhythmic medication use. In conclusion, although antiarrhythmic medication and beta blocker use in patients with VT increased over time, <1 in 4 patients were on an antiarrhythmic medication and only 65% of the patients were on a beta blocker.</description><subject>Ablation</subject><subject>Acute coronary syndromes</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amiodarone</subject><subject>Amiodarone - therapeutic use</subject><subject>Anemia</subject><subject>Anomalies</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Antiarrhythmics</subject><subject>Arrhythmia</subject><subject>Atenolol</subject><subject>Cancer</subject><subject>Cardiac arrhythmia</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cerebral infarction</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Circulation</subject><subject>Classification</subject><subject>Clinical trials</subject><subject>Codes</subject><subject>Complications</subject><subject>Congenital defects</subject><subject>Congestive heart failure</subject><subject>Coronary artery</subject><subject>Coronary artery disease</subject><subject>Coronary vessels</subject><subject>Damage</subject><subject>Databases, Factual</subject><subject>Death, Sudden, Cardiac - prevention & control</subject><subject>Defibrillators, Implantable</subject><subject>Diabetes mellitus</subject><subject>Diagnosis</subject><subject>Drugs</subject><subject>Electric Countershock</subject><subject>Electrocardiography</subject><subject>Enrollments</subject><subject>Female</subject><subject>Generic drugs</subject><subject>Government programs</subject><subject>Guidelines</subject><subject>Health care</subject><subject>Health risks</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Incidence</subject><subject>Intervention</subject><subject>Ischemia</subject><subject>Kidney transplantation</subject><subject>Logistic Models</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Mathematical models</subject><subject>Medical instruments</subject><subject>Medicare</subject><subject>Medicare Part D</subject><subject>Mexiletine - therapeutic use</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Patients</subject><subject>Population studies</subject><subject>Populations</subject><subject>Prescription drugs</subject><subject>Prevention</subject><subject>Quality of life</subject><subject>Ranolazine - therapeutic use</subject><subject>Regression analysis</subject><subject>Renal failure</subject><subject>Risk</subject><subject>Skin</subject><subject>Sodium Channel Blockers - therapeutic use</subject><subject>Sotalol - therapeutic use</subject><subject>Statistical tests</subject><subject>Stroke</subject><subject>Survival</subject><subject>Tachycardia, Ventricular - therapy</subject><subject>Terminology</subject><subject>Transplants & implants</subject><subject>United States</subject><subject>Ventricle</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkkuLFDEQgBtR3HH1JygBL166rUr6eVGWWR8LKwru6jGkk2ombT_GJL0w_8CfbZoZFfbiKRR8Vamqr5LkOUKGgOXrPlNjr5UzGQesMsAMBDxINlhXTYoNiofJBgB42mDenCVPvO9jiFiUj5MzXoscRQmb5NetJzZ37GIKVjm3O4TdaDX7RMZqFew8eWanU-iIfVEusMv4BEtT8Oy7DTumJnY17gc1BdUOxLaxKTvfkQvk0kvqbOvsMKgwu0ga9i0mOquXQTl2o_TusA5h1dPkUacGT89O73ly-_7dzfZjev35w9X24jrVeV6H1PAKOfC8besiN8bUHZZFq5BaoagC0RUNqJpXuSkK6lAY6EpBVVULFIRdIc6TV8e6ezf_XMgHOVqvKTY40bx4iXWNvGwA8oi-vIf28-Km2N1KRYwXZROp4khpN3vvqJN7Z0flDhJBrqpkL0-q5KpKAsqoKua9OFVf2pHM36w_biLw9ghQXMedJSe9jlvX0YUjHaSZ7X-_eHOvgh7sFE0OP-hA_t800nMJ8ut6L-u5YCUAeVOJ38QyvO8</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Pokorney, Sean D., MD, MBA</creator><creator>Mi, Xiaojuan, PhD</creator><creator>Hammill, Bradley G., DrPH</creator><creator>Allen LaPointe, Nancy M., PharmD, MHS</creator><creator>Curtis, Lesley H., PhD</creator><creator>Al-Khatib, Sana M., MD, MHS</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4345-0816</orcidid></search><sort><creationdate>20170501</creationdate><title>Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia</title><author>Pokorney, Sean D., MD, MBA ; Mi, Xiaojuan, PhD ; Hammill, Bradley G., DrPH ; Allen LaPointe, Nancy M., PharmD, MHS ; Curtis, Lesley H., PhD ; Al-Khatib, Sana M., MD, MHS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-d2712024bb854ddd8f165ba1eb3ae703f590a8274d55ef13d0f63e778313e1f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Ablation</topic><topic>Acute coronary syndromes</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amiodarone</topic><topic>Amiodarone - therapeutic use</topic><topic>Anemia</topic><topic>Anomalies</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Antiarrhythmics</topic><topic>Arrhythmia</topic><topic>Atenolol</topic><topic>Cancer</topic><topic>Cardiac arrhythmia</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cerebral infarction</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Circulation</topic><topic>Classification</topic><topic>Clinical trials</topic><topic>Codes</topic><topic>Complications</topic><topic>Congenital defects</topic><topic>Congestive heart failure</topic><topic>Coronary artery</topic><topic>Coronary artery disease</topic><topic>Coronary vessels</topic><topic>Damage</topic><topic>Databases, Factual</topic><topic>Death, Sudden, Cardiac - prevention & control</topic><topic>Defibrillators, Implantable</topic><topic>Diabetes mellitus</topic><topic>Diagnosis</topic><topic>Drugs</topic><topic>Electric Countershock</topic><topic>Electrocardiography</topic><topic>Enrollments</topic><topic>Female</topic><topic>Generic drugs</topic><topic>Government programs</topic><topic>Guidelines</topic><topic>Health care</topic><topic>Health risks</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Incidence</topic><topic>Intervention</topic><topic>Ischemia</topic><topic>Kidney transplantation</topic><topic>Logistic Models</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Mathematical models</topic><topic>Medical instruments</topic><topic>Medicare</topic><topic>Medicare Part D</topic><topic>Mexiletine - therapeutic use</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Patients</topic><topic>Population studies</topic><topic>Populations</topic><topic>Prescription drugs</topic><topic>Prevention</topic><topic>Quality of life</topic><topic>Ranolazine - therapeutic use</topic><topic>Regression analysis</topic><topic>Renal failure</topic><topic>Risk</topic><topic>Skin</topic><topic>Sodium Channel Blockers - therapeutic use</topic><topic>Sotalol - therapeutic use</topic><topic>Statistical tests</topic><topic>Stroke</topic><topic>Survival</topic><topic>Tachycardia, Ventricular - therapy</topic><topic>Terminology</topic><topic>Transplants & implants</topic><topic>United States</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pokorney, Sean D., MD, MBA</creatorcontrib><creatorcontrib>Mi, Xiaojuan, PhD</creatorcontrib><creatorcontrib>Hammill, Bradley G., DrPH</creatorcontrib><creatorcontrib>Allen LaPointe, Nancy M., PharmD, MHS</creatorcontrib><creatorcontrib>Curtis, Lesley H., PhD</creatorcontrib><creatorcontrib>Al-Khatib, Sana M., MD, MHS</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pokorney, Sean D., MD, MBA</au><au>Mi, Xiaojuan, PhD</au><au>Hammill, Bradley G., DrPH</au><au>Allen LaPointe, Nancy M., PharmD, MHS</au><au>Curtis, Lesley H., PhD</au><au>Al-Khatib, Sana M., MD, MHS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>119</volume><issue>9</issue><spage>1401</spage><epage>1406</epage><pages>1401-1406</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012. Patients were identified through a search for antiarrhythmic medication fills with a supply covering January 1 of the cohort year. Adjusted logistic regression modeling evaluated the association between patient characteristics and antiarrhythmic medication use. The 2007 (n = 2,334) and 2012 (n = 3,892) Medicare Part D cohorts had similar demographics: median age 76 years, 64%-67% male, and 87%-89% white. Of the 2007 cohort, 1,380 (59%) patients were on a beta blocker, and 484 (20.7%) were on an antiarrhythmic medication (70% amiodarone and 20% sotalol). Between 2007 and 2012, there was a statistically significant higher use of any antiarrhythmic medication (p = 0.014), beta blockers (p <0.0001), mexiletine (p = 0.005), and ranolazine (p <0.0001), while amiodarone use remained unchanged (p = 0.53). After multivariable adjustment, male gender and renal disease were associated with higher antiarrhythmic medication use. In conclusion, although antiarrhythmic medication and beta blocker use in patients with VT increased over time, <1 in 4 patients were on an antiarrhythmic medication and only 65% of the patients were on a beta blocker.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28341360</pmid><doi>10.1016/j.amjcard.2017.01.030</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4345-0816</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2017-05, Vol.119 (9), p.1401-1406 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1881269004 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Ablation Acute coronary syndromes Adrenergic beta-Antagonists - therapeutic use Aged Aged, 80 and over Amiodarone Amiodarone - therapeutic use Anemia Anomalies Anti-Arrhythmia Agents - therapeutic use Antiarrhythmics Arrhythmia Atenolol Cancer Cardiac arrhythmia Cardiomyopathy Cardiovascular Cardiovascular disease Cardiovascular diseases Cerebral infarction Chronic obstructive pulmonary disease Circulation Classification Clinical trials Codes Complications Congenital defects Congestive heart failure Coronary artery Coronary artery disease Coronary vessels Damage Databases, Factual Death, Sudden, Cardiac - prevention & control Defibrillators, Implantable Diabetes mellitus Diagnosis Drugs Electric Countershock Electrocardiography Enrollments Female Generic drugs Government programs Guidelines Health care Health risks Heart Heart attacks Heart failure Hospitals Humans Hypertension Incidence Intervention Ischemia Kidney transplantation Logistic Models Lung diseases Male Mathematical models Medical instruments Medicare Medicare Part D Mexiletine - therapeutic use Mortality Myocardial infarction Patients Population studies Populations Prescription drugs Prevention Quality of life Ranolazine - therapeutic use Regression analysis Renal failure Risk Skin Sodium Channel Blockers - therapeutic use Sotalol - therapeutic use Statistical tests Stroke Survival Tachycardia, Ventricular - therapy Terminology Transplants & implants United States Ventricle |
| title | Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Antiarrhythmic%20Medications%20in%20Medicare%20Part%20D%20Patients%20With%20an%20Implantable%20Cardioverter-Defibrillator%20and%20Ventricular%20Tachycardia&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Pokorney,%20Sean%20D.,%20MD,%20MBA&rft.date=2017-05-01&rft.volume=119&rft.issue=9&rft.spage=1401&rft.epage=1406&rft.pages=1401-1406&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2017.01.030&rft_dat=%3Cproquest_cross%3E1888122569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1888122569&rft_id=info:pmid/28341360&rft_els_id=S0002914917301297&rfr_iscdi=true |